ArticleInternational journal of ophthalmology2022
Anti-inflammatory effects of α-humulene and β-caryophyllene on pterygium fibroblasts.
Article in International journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Comparative metabolomic profiling and bioactivities of essential oils from different organs and geographic origins ofFood chemistry: X · 2026Article
- Chemical Profiling and Multimodal Anti-Inflammatory Activity ofMolecules (Basel, Switzerland) · 2026Article
- Antioxidant and selective cytotoxic activity of Dipterocarpus obtusifolius flower extract against gastrointestinal cancer, with bioactive component profiling.BMC complementary medicine and therapies · 2026Article
- Regulatory Effects ofFood science & nutrition · 2025Article
- Impact of Clove Essential Oil on the Intestinal Flora in Mice Infected withMolecules (Basel, Switzerland) · 2025Article
- Neuroprotective Properties of Clove (Biomolecules · 2025Review
- Prevalence of pterygium and pinguecula and their risk factors: Tehran Geriatric Eye Study.International journal of ophthalmology · 2025Article
- Plant-Derived Compounds in Hemp Seeds (Molecules (Basel, Switzerland) · 2024Review
- 3D Printed Bigel: A Novel Delivery System for Cannabidiol-Rich Hemp Extract.Gels (Basel, Switzerland) · 2024Article
- Article
- The Clinical Translation of α-humulene - A Scoping Review.Planta medica · 2024Article
- Artificial intelligence assisted pterygium diagnosis: current status and perspectives.International journal of ophthalmology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the anti-inflammatory effects of the sesquiterpenes α-humulene and β-caryophyllene on pterygium fibroblasts.
methodsPrimary cultures of pterygium fibroblasts were established. Third passage pterygium fibroblasts were exposed to α-humulene and β-caryophyllene separately and together. The cell viability was assessed by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay at 12, 24, 48, and 72h after exposure. The levels of the inflammatory cytokines interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor (TNF)-α and IL-10 in the conditioned culture medium were assessed by enzyme-linked immunosorbent assay (ELISA) at 12, 24 and 48h after exposure. Data were statistically analyzed using Friedman repeated measures analysis of variances on ranks.
resultsThe 25 µmol/L β-caryophyllene induced significant decrease in the IL-6 production by pterygium fibroblasts 48h after the exposure (
conclusionThe exposure to 25 µmol/L of β-caryophyllene significantly reduce the production of IL-6 by pterygium fibroblasts after 48h. This sesquiterpene may be a potential alternative adjuvant agent for the treatment of pterygium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.